Key messages

1. IMI contributes to quality of life in Europe

2. IMI contributes to the competitiveness of the European life sciences sector

3. IMI contributes to sharing of data and information
The diverse IMI community

- 594 Academic & research teams
- 363 EFPIA teams
- 109 SMEs
- 18 patient organisations
- 9 regulators

42 projects

€1.6 bn committed

Collective intelligence networks
Improved R&D productivity of pharma industries
Innovative approaches for unmet public health needs
IMI tackles diverse research areas
Brain disorders: a challenge for Europe

1 in 3 Europeans affected

€798 bn costs to economy / year

Developing new drugs takes longer & costs more than for other diseases
Sharing data to improve clinical trials for schizophrenia

By redesigning clinical trials, you could:

- make them shorter (6 weeks → 4 weeks)
- require fewer people (79 → 46 patients per arm)
- cut costs (savings of €2.8 million)
- gain insights into effects of treatment on negative symptoms (e.g. lack of emotion)
Autism – a common disorder

- Affects 1 in 110
- Lifelong condition
- Difficulties in social interaction & communication, unusual repetitive behaviours
- Major impact on families & carers

Treatments designed specifically for autism
EU-AIMS – European action on autism

- New insights into underlying causes
- Could the brain changes be reversed?
- 2 major clinical trials for early detection and monitoring of ASD in children
- Working with regulators on treatment guidelines
Antimicrobial resistance: a growing threat

25 000 Europeans killed / year

€1.5 bn costs to economy / year

2 new classes of antibiotics in the last 30 years
IMI – New Drugs for Bad Bugs

• €229 million budget

• Scientific challenges

• New models of collaboration

• Regulatory environment

• Incentives for industry to reinvest in the area

• Clinical trials network: 261 clinical sites in 32 countries
IMI: a partner for SMEs

• IMIDIA generated the first human pancreatic beta cell line – a major breakthrough in diabetes research
• A French SME was at the heart of the research

‘Thanks to this collaboration, the robustness of our beta cells has been validated by large pharma companies – a major advantage for a biotechnology company like Endocells.’
– Anne-Fabienne Weitsch, CEO of Endocells
IMI contributes to drug safety

- SAFE-T project
  - 153 potential biomarker candidates for drug-induced injury of kidney, liver and vascular system evaluated
  - 17 exploratory clinical studies started or completed
  - Dialogue with regulatory agencies
IMI – joining forces for drug discovery

European Lead Factory

• An industry-like lead discovery platform available for public projects

• Joint European Compound Collection (Scotland)
  – 300 000 compounds from industry partners - in place ✔
  – 200 000 compounds from public partners

• European Screening Centre (the Netherlands)
  – 1st screen completed successfully ✔

• Sustainable model to establish independent business entity
IMI – putting patients at the heart of drug development

- U-BIOPRED – towards personalised medicine for severe asthma
- The challenge – to recruit 1 025 people
- Patients involved in project as partners & through ethics board, safety monitoring board, and patient input platform
- Offered patients’ perspective on recruitment, study design, and project communication
THANK YOU!

www.imi.europa.eu
Twitter: @IMI_JU